Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+16.05%
-1.95%
-15.72%
-7.33%
-7.23%
EPRX
Eupraxia Pharmaceuticals
$6.07
Login to see Eupraxia Pharmaceuticals (EPRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Chart
$5.38 (+12.83%)
$5.4 (+12.41%)
$5.4 (+12.41%)
$5.4 (+12.41%)
EPRX has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
EPRX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
EPRX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
EPRX Street view is extremely bullish and have negative views on the near-term outlook
EPRX Earnings
The TTM reflects 12-month period, providing review of EPRX financial performance.
The company financial health has deteriorated over the past year
Financial Score
What is EPRX current stock price?
What are EPRX stock strengths?
What risks are associated with EPRX stock?
When is EPRX next earnings report?
What is EPRX market cap and volume?
What is EPRX's current Stock IQ?
Should I buy EPRX stock right now?
Is EPRX a Strong Buy right now?
What does a 'Strong Buy' rating mean for EPRX?
What does a 'Strong Sell' rating mean for EPRX?
What factors influence EPRX's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+16.05%
-1.95%
-15.72%
-7.33%
-7.23%
EPRX
Eupraxia Pharmaceuticals
Current Price
$6.07
Login to unlock Eupraxia Pharmaceuticals (EPRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$5.38 (+12.83%)
$5.4 (+12.41%)
$5.4 (+12.41%)
$5.4 (+12.41%)
EPRX Analysts Opinion
EPRX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
EPRX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
EPRX Street view is extremely bullish and have negative views on the near-term outlook
EPRX has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
EPRX Earnings
The TTM data reflects the most recent 12-month period, providing overview of EPRX financial performance.
EPRX Financial Health
The company financial health has deteriorated over the past year
Financial Score
EPRX Latest Analysis
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis and Plans for Expansion of EP-104GI Development Programs. VICTORIA British Columbia Sept. 29 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (Eupraxia or the Company) (NASDAQ:EPRX) (TSX:EPRX) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local controlled drug delivery for diseases with significant unmet n
Mon Sep 29, 2025
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option. ) (TSX:) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™. technology designed to optimize local controlled drug delivery for applications with significant unmet need is pleased to announce the successful closing of its previously announced public offering (the ".Offering".) of 14636363 common shares of the Company (the Common Shar
Wed Sep 24, 2025
Eupraxia Pharmaceuticals prices $70M share offering.
Tue Sep 23, 2025
Eupraxia Pharmaceuticals announces public offering of common shares.
Mon Sep 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
EPRX Stock trends
EPRX Stock performance
EPRX Stock analysis
EPRX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders